A recent report has detailed the challenges facing the pharma
industry as the generic flood gates open, with the constant advice
to start planning early still apparently not heeded by a
bewildering number of firms.
With IMS Health's annual forecast for the pharma industry
predicting slower approvals, more black box warnings and the
continuation of the 'wave of genericization,' the shift by
pharma firms to refocus and reinvent...
A report to be published next week predicts that US and EU pharmas
will lose up to $100bn in revenues over the next five years as
generic products take advantage of major branded products losing